PDCD1 and non-Hodgkin lymphoma: In conclusion, our multicenter cohort study revealed a high prevalence of EBV+ in patients with AR‐NHL characterized by elevated tissue levels of PD‐1, which is associated with a particularly poor prognosis in the era of chemoimmunotherapy.